|Bid||131.00 x 100|
|Ask||0.00 x 500|
|Day's Range||140.00 - 145.81|
|52 Week Range||130.15 - 184.00|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||16.67|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||186.22|
Bruce Cozadd has been the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) since 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
DUBLIN, Nov. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia, a sleep disorder characterized by chronic and disabling excessive daytime sleepiness (daytime periods of irrepressible need to sleep or daytime lapses into sleep) that is not caused by other conditions known to induce excessive daytime sleepiness. Other symptoms of idiopathic hypersomnia may include prolonged nighttime sleep, long and unrefreshing naps and difficulty waking up from nocturnal sleep or daytime naps.
Nine abstracts, including two oral presentations, accepted for Jazz hematology/oncology portfolio, focusing on leukemia and complications of stem cell transplantation DUBLIN , Nov. 28, 2018 /PRNewswire/ ...
Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017, which reflected ~17% YoY (year-over-year) growth. Defitelio reported net revenues of $111.7 million during the first nine months of 2018—compared to $97.4 million during the same period in 2017, which reflects ~15% YoY growth.
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
Jazz Pharmaceuticals plc (JAZZ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
DUBLIN , Nov. 9, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, ...
Jazz Pharmaceuticals stock collapsed Wednesday after the drugmaker missed third-quarter expectations for cancer treatment Vyxeos and cut its guidance for 2018. Shares lost more than 10%.
Jazz Pharmaceuticals shares crumbled late Tuesday after the top-rated pharma stock missed sales expectations in the third-quarter and issued 2018 guidance that lagged analyst views.
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
"This is the first new chemotherapy in forty years for adults with specific types of newly diagnosed secondary AML, a particularly aggressive cancer that typically affects older people and has a high mortality rate," said Dr. Nigel Russell, Professor of Haematology, Faculty of Medicine & Health Sciences at the University of Nottingham. "I am pleased that NICE has recognised the value of this medicine for adults with secondary AML.
Stock futures rose sharply on election results: Democrats won the House but the GOP held the Senate. Seven leaders were big stock market movers on earnings.
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at four upcoming investor conferences. Stifel ...
Jazz (JAZZ) delivered earnings and revenue surprises of 7.51% and -2.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had profit of $2.41 per share. Earnings, adjusted for asset impairment costs and stock option expense, were $3.58 per share. The results topped Wall Street expectations. ...
GAAP Diluted EPS of $2.41 ; Adjusted Diluted EPS of $3.58 Reflects Growth of 11% Total Revenues Increased 14% to $469 Million Xyrem Product Sales Increased 18% to $357 Million Received EU Marketing Authorization ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
This approval of Xyrem by the FDA marks the first medicine approved to treat cataplexy or excessive daytime sleepiness in children and adolescents with narcolepsy ages seven and older Efficacy and safety ...